阿魏酸哌嗪联合厄贝沙坦治疗糖尿病肾病的疗效观察

Curative effect of piperazine ferulate combined with irbesartan on diabetic kidney disease

目的:探讨阿魏酸哌嗪联合厄贝沙坦对早期糖尿病肾病(diabetic kidney disease,DKD)患者的肾脏保护作用。方法:将2008年1月至2011年1月在我院肾内科接受治疗的早期DKD患者80例,随机分为2组:①厄贝沙坦(A组);②阿魏酸哌嗪+厄贝沙坦(B组)。两组患者均采用常规的治疗方法,A组在常规治疗的基础上加用厄贝沙坦片,而B组则加用阿魏酸哌嗪和厄贝沙坦治疗,治疗8周后评价各组患者治疗前后尿白蛋白排泄率、血清肌酐及尿β2微球蛋白等的改变情况,组内进行治疗前后的比较,两组之间进行治疗后疗效的比较。结果:A、B两组治疗后的尿白蛋白排泄率、尿β2微球蛋白与治疗前相比差异有统计学意义(P<0.05);两组患者治疗后的疗效相比,差异具有统计学意义(P<0.01)。结论:阿魏酸哌嗪联合厄贝沙坦可明显改善早期DKD患者的肾功能,并能明显的提高临床疗效,值得临床的广泛应用。

Objective：To assess the protective effects of piperazine ferulate and irbesartan on early diabetic kidney disease（DKD）. Methods ：80 patients with early DKD of the department of nephrology in our hospital from January 2008 to January 2011 were randomly divided into two groups ： （ 1 ） irbesartan（ group A） ; （2） piperazine ferulate ＋ irbesartan （ group B）. All of the cases were given regular treatment. In addition, group A were given irbesartan, group B were given piperazine ferulate and irbesartan. Urinary albumin excre- tion rate （UAER） , serum creatinine （Scr） and β2-microglobulin （62-MG） were assessed at the same time before and after the treatment of 8 weeks among every group. After the treatment of 8 weeks, Clinical curative effects of posttreatment were compared between the two groups. Results： The significant difference that UAER and β2-MG of Group A and B before and after the treatment were found （P 〈 0. 05 ）. The clinical curative effects of posttreatment of the two groups were statistically significant （ P 〈 0.01 ）. Conclusion ： The renal function of the patients with early DKD can be significantly improved by the Piperazine ferulate combined with irbesartan, and it also can significantly improve the clinical outcomes. It is worthy of a wide range of clinical applications.